Withanone as an inhibitor of survivin: A potential drug candidate for cancer therapy

Journal of Biotechnology

Volumn 168, Issue 2, 2013, Pages 229-233

  Wadegaonkar, Varsha P ^a   Wadegaonkar, Prasad A ^a  

^a SANT GADGE BABA AMRAVATI UNIVERSITY   (India)

Author keywords

Apoptosis; Cancer; Inhibitor of apoptosis; Survivin; Withania somnifera; Withanone

Indexed keywords

CANCER; INHIBITOR OF APOPTOSIS; SURVIVIN; WITHANIA SOMNIFERA; WITHANONE;

BINDING ENERGY; CELL DEATH; CHROMOSOMES; DISEASES;

ONCOLOGY;

ANTINEOPLASTIC AGENT; CASPASE; LIGAND; SURVIVIN; UNCLASSIFIED DRUG; WITHANONE;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER THERAPY; DRUG BINDING; LIGAND BINDING; MITOSIS; MOLECULAR DOCKING; PLANT ROOT; PRIORITY JOURNAL; WITHANIA SOMNIFERA;

WITHANIA SOMNIFERA;

APOPTOSIS; CANCER; INHIBITOR OF APOPTOSIS; SURVIVIN; WITHANIA SOMNIFERA; WITHANONE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INHIBITOR OF APOPTOSIS PROTEINS; MITOSIS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; TRITERPENES;

EID: 84885834652     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2013.08.028     Document Type: Article

References (49)

1. Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., Altieri D.C. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse. Am. J. Pathol. 1998, 152(1):43-49.
2. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer. 2003, 3(1):46-54.
3. Altieri D.C. Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 2010, 430(2):199-205.
4. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 38:917-921.
5. Anjaneyulu A.S.R., Rao D.S., Lequesne P.W. Withanolides, biologically active natural steroidal lactones: a review. Studies in Natural Products Chemistry (F) 1997, vol. 20:135-261. Elsevier.
6. Atlasi Y.M., Seyed J.Z., Seyed A.M. Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer. Cancer Detect. Prev. 2009, 32(4):308-313.
7. Berman H.M., Battistuz T., Bhat T.N., Bluhm W.F., Bourne P.E., Burkhardt K., Feng Z., Gilliland G.L., Iype L., Jain S., Fagan P., Marvin J., Padilla D., Ravichandran V., Schneider B., Thanki N., Weissig H., Westbrook J.D., Zardecki C. The protein data bank. Acta Crystallogr. D: Biol. Crystallogr. 2002, 58(Pt. 6 No. 1):899-907.
8. Boehm H. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J. Comput. Aided Mol. Des. 1992, 6:61-78.
9. Ceballos-Cancino G., Espinosa M., Maldonado V., Melendez-Zajgla J. Regulation of mitochondrial Smac/DIABLO selective release by survivin. Oncogene 2007, 26:7569-7575.
10. Chantalat L., Skoufias D.A., Kleman J.P., Jung B., Dideberg O., Margolis R.L. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol. Cell 2000, 61:183-189.
11. Chai J., Du C., Wu J.W., Kyin S., Wang X., Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000, 406(6798):855-862.
12. Cheung C.H.A., Chen H.H., Kuo C.C., Chang C.C., Coumar M.S., Hsieh H.P., Jang-Yang Chang J.Y. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol. Cancer 2009, 8:43.
13. Cossu F., Mastrangelo E., Milani M., Sorrentino G., Lecis D., Delia D., Manzoni L., Seneci P., Scolastico C., Bolognesi M. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. Biochem. Biophys. Res. Commun. 2009, 378:162-167.
14. Cossu F., Malvezzi F., Canevari G., Mastrangelo E., Lecis D., Delia D., Seneci P., Scolastico C., Bolognesi M., Milani M. Recognition of Smac-mimetic compounds by the BIR domain of cIAP1. Protein Sci. 2010, 19:2418-2429.
15. DeLano W. The PyMOL Molecular Graphics System 2002 2002, 2002. DeLano Scientific, San Carlos, CA.
16. Deveraux Q.L., Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999, 13(3):239-252.
17. Dohi T., Okada K., Xia F., Wilford C.E., Samuel T., Welsh K., Marusawa H., Zou H., Armstrong R., Matsuzawa S., Salvesen G.S., Reed J.C., Altieri D.C. An IAP-IAP complex inhibits apoptosis. J. Biol. Chem. 2004, 279:34087-34090.
18. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome C dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
19. Du J., Kelly A.E., Funabiki H., Patel D.J. Structural basis for recognition of H3T3ph and Smac/DIABLO N-terminal peptides by human survivin. Structure 2012, 20:185-195.
20. Duffya M.J., O'Donovanc N., Brennand D.J., Gallagherd W.M., Ryana B.M. Survivin: a promising tumor biomarker. Cancer Lett. 2007, 249(1):49-60.
21. Dym O., Xenarios I., Ke H.M., Colicelli J. Molecular docking of competitive phosphodiesterase inhibitors. Mol. Pharmacol. 2002, 61(1):20-25.
22. Fukuda S., Pelus L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 2006, 5(5):1087-1098.
23. Grover A., Shandilya A., Bisaria V., Sundar D. Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes. BMC Genom. 2010, 11(Suppl 4):S4-S15.
24. Gyrd-Hansen M., Meier P. IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer. Nat. Rev. Cancer. 2010, 10:561-574.
25. Hinds M.G., Norton R.S., Vaux D.L., Day C.L. Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat. Nat. Struct. Biol. 1999, 6(7):648-651.
26. Jha K., Shukla M., Pandey M. Survivin expression and targeting in breast cancer. Surg. Oncol. 2012, 21(2):125-131.
27. Jayaprakasam B., Zhang Y., Seeram N.P., Nair M.G. Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci. 2003, 74(1):125-132.
28. Li L., Thomas R.M., Suzuki H., De Brabander J.K., Wang X., Harran P.G. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004, 305:1471-1474.
29. McNeish I.A., Bell S., McKay T., Tenev T., Marani M., Lemoine N.R. Expression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9 mediated pathway. Exp. Cell Res. 2003, 286(2):186-198.
30. Morizane Y., Honda R., Fukami K., Yasuda H. X-linked inhibitor of apoptosis functions as ubiquitin ligase towards mature caspase-9 and cytosolic Smac/DIABLO. J. Biochem. (Tokyo) 2005, 137:125-132.
31. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A. Automated docking using a Lamarckian genetic algorithm and an empiri-cal binding free energy function. J. Comput. Chem. 1998, 19(14):1639-1662.
32. Petersen S.L., Peyton M., Minna J.D., Wang X. Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11936-11941.
33. Rao M.S., Olson A.J. Modelling of Factor Xa-inhibitor complexes: a computational flexible docking approach. Proteins 1999, 34(2):173-183.
34. Rappe A.K., Casewit C.J., Colwell K.S., Goddard W.A., Skiff W.M. UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations. J. Am. Chem. Soc. 1992, 114(25):10024-10035.
35. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 2009, 35(7):553-562.
36. Seneci P., Bianchi A., Battaglia C., Belvisi L., Bolognesi M., Caprini A., Cossu F., Franco E., Matteo M., Delia D., Drago C., Khaled A., Lecis D., Manzoni L., Marizzoni M., Mastrangelo E., Milani M., Motto I., Moroni E., Potenza D., Rizzo V., Servida F., Turlizzi E., Varrone M., Vasile F., Scolastico C. Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy. Bioorg. Med. Chem. 2009, 17:5834-5856.
37. Shah N., Kataria H., Kaul S.C., Ishii T., Kaur G., Wadha R. Effect of the alcoholic extract of Ashwagandha leaves and its components on proliferation, migration, and differentiation of glioblastoma cells: combinational approach for enhanced differentiation. Cancer Sci. 2009, 100(9):1740-1747.
38. Vaishnavi K., Saxena N., Shah N., Singh R., Manjunath K., Uthayakumar M., Kanaujia S.P., Kaul S.C., Sekar K., Wadhwa R. Differential activities of the two closely related withanolides, withaferin A and withanone: bioinformatics and experimental evidences. PLos ONE 2012, 7(9):e44419.
39. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., Zobel K., Dynek J.N., Elliott L.O., Wallweber H.J., Flygare J.A., Fairbrother W.J., Deshayes K., Dixit V.M., Vucic D. IAP antagonists induce autoubiquitination of c-IAPs. NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
40. Verhagen A.M., Coulson E.J., Vaux D.L. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. 2001, 2(7). REVIEWS3009.
41. Verhagen A.M., Vaux D.L. Cell death regulation by mammalian IAP antagonist DIABLO/Smac. Apoptosis 2002, 7:163-166.
42. Vince J.E., Wong W.W-L., Khan N., Feltham R., Chau D., Ahmed A.U., Benetatos A.C., Chunduru S.K., Condon S., McKinlay M., Brink R., Leverkus M., Tergaonkar V., Schneider P., Callus B., Koentgen F., Vaux D., Silke J. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 2007, 131:682-693.
43. Wadegaonkar P.A., Bhagwat K.A., Rai M. Direct rhizogenesis and establishment of fast growing normal root organ culture of Withania somnifera Dunal. Plant Cell Tissue Organ Cult. 2006, 84:100202-100204.
44. Widodo N., Kaur K., Shrestha B.G., Takagi Y., Ishii T., Wadhwa R., Kaul S.C. Selective killing of cancer cells by leaf extract of Ashwagandha: identification of a tumor-inhibitory factor and the first molecular insights to its effect. Clin. Cancer Res. 2007, 13:2298-2306.
45. Widodo N., Takagi Y., Shrestha B.G., Ishii T., Kaul S.C., Wadhwa R. Selective killing of cancer cells by leaf extract of Ashwagandha: components, activity and pathway analyses. Cancer Lett. 2008, 262:37-47.
46. Widodo N., Priyandoko D., Shah N., Wadhwa R., Kaul S.C. Selective killing of cancer cells by Ashwagandha leaf extract and its component withanone involves ROS signaling. PLoS ONE 2010, 5(10):e13536. 10.1371/journal.pone.0013536.
47. Wu G., Chai J., Suber T.L., Wu J.W., Du C., Wang X., Shi Y. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000, 408(6815):1008-1012.
48. Zobel K., Wang L., Varfolomeev E., Franklin M.C., Elliott L.O., Wallweber H.J., Okawa D.C., Flygare J.A., Vucic D., Fairbrother W.J., Deshayes K. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem. Biol. 2006, 1:525-533.
49. Zaffaroni N., Pennati M., Daidone M.G. Survivin as a target for new anticancer interventions. J. Cell Mol. Med. 2005, 9:360-372.